MiMedx Group, Inc $MDXG Stock Position Trimmed by Trigran Investments Inc.

Trigran Investments Inc. cut its stake in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 8.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 7,701,028 shares of the company’s stock after selling 689,430 shares during the period. MiMedx Group makes up 9.7% of Trigran Investments Inc.’s portfolio, making the stock its 3rd biggest position. Trigran Investments Inc. owned approximately 0.05% of MiMedx Group worth $53,753,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in MDXG. CWM LLC raised its position in shares of MiMedx Group by 63.8% during the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after buying an additional 1,892 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in MiMedx Group by 1,808.4% in the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock valued at $46,000 after acquiring an additional 7,107 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in MiMedx Group during the third quarter valued at about $54,000. Headlands Technologies LLC bought a new stake in MiMedx Group during the second quarter worth about $72,000. Finally, Osaic Holdings Inc. increased its position in shares of MiMedx Group by 57.2% during the 2nd quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock valued at $79,000 after purchasing an additional 4,708 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

Analyst Upgrades and Downgrades

MDXG has been the subject of several research reports. Citigroup began coverage on MiMedx Group in a research note on Monday, February 23rd. They issued a “market outperform” rating for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Cantor Fitzgerald cut their price target on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. Wall Street Zen cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Lake Street Capital lowered their target price on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 20th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.60.

MiMedx Group Price Performance

MDXG stock opened at $4.75 on Friday. The stock has a market capitalization of $705.69 million, a price-to-earnings ratio of 14.84 and a beta of 1.60. The firm’s 50-day moving average price is $5.52 and its two-hundred day moving average price is $6.51. The company has a current ratio of 4.32, a quick ratio of 3.92 and a debt-to-equity ratio of 0.06. MiMedx Group, Inc has a 12-month low of $4.70 and a 12-month high of $8.20.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. The company had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. As a group, equities analysts predict that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.